Internal Reference Number: FOI_6742
Date Request Received: 17/08/2022 00:00:00
Date Request Replied To: 31/08/2022 00:00:00
This response was sent via: By Email
Request Summary: Treatment of Haemophilia A
Request Category: Researcher
| Question Number 1: In the last three months, how many patients have been treated by your haemophilia centre with the following products? • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (standalone) • Hemlibra in combination with any Factor VIII • NovoEight • NovoSeven RT • Obizur • Refacto AF | |
| Answer To Question 1: This information covers May, June and July 2022. • Advate <5 • Adynovi 0 • Elocta 0 • Esperoct 0 • Factor Eight Inhibitor Bypass Activity (FEIBA) 0 • Hemlibra (standalone) 0 • Hemlibra in combination with any Factor VIII 0 • NovoEight 0 • NovoSeven RT 0 • Obizur 0 • Refacto AF 0 | |
| Question Number 2: In the last three months, how many patients were treated with the following products for severe Haemophila A ONLY? • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (standalone) • Hemlibra in combination with any Factor VIII • NovoEight • NovoSeven RT • Obizur • Refacto AF | |
| Answer To Question 2: This information covers May, June and July 2022. • Advate <5 • Adynovi 0 • Elocta 0 • Esperoct 0 • Factor Eight Inhibitor Bypass Activity (FEIBA) 0 • Hemlibra (standalone) 0 • Hemlibra in combination with any Factor VIII 0 • NovoEight 0 • NovoSeven RT 0 • Obizur 0 • Refacto AF 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
